Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease

Shares of Novo Nordisk climbed astir 5% Monday aft the company's blockbuster Wegovy obesity cause received accelerated support from the U.S. Food and Drug Administration to dainty a superior liver disease.

The institution connected Friday said that it was granted the support for the attraction of metabolic dysfunction-associated steatohepatitis (MASH) successful adults with mean to precocious liver fibrosis, successful operation with a reduced calorie fare and accrued carnal activity.

Novo Nordisk shares were up 5.05% by 9:59 a.m. London clip (4:45 a.m. E.T.).

This is simply a processing story. Please cheque backmost for updates.